<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166437</url>
  </required_header>
  <id_info>
    <org_study_id>IRB TH No 6-3</org_study_id>
    <nct_id>NCT02166437</nct_id>
  </id_info>
  <brief_title>Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese</brief_title>
  <official_title>Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomidahama Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomidahama Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators would like to analyze the bone mineral density (BMD) , bone
      turnover makers, and fracture prevention effects of bisphosphonate and denosumab randomly
      divided following daily teriparatide in Japanese patients under clinical practice. The
      participants are treated in the investigators hospital, who are under severe osteoporotic
      condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Registry criteria: Patients treated in the investigators hospital using teriparatide.
      Enrolled patients are severe osteoporosis; more than two previous osteoporotic fractures, low
      BMD (&lt; young adult mean 65%).

      Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months
      Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds
      participants
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical results of bisphosphonate vs. denosmab following daily teriparatide treatment</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The investigators plan to analyze 500 patients who treated with bisphosphonate or denosmab following daily teriparatide treatment.
We investigate changes in BMD and bone turnover markers.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <description>Patients treated with alendronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minodronate</arm_group_label>
    <description>Patients treated with minodronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosmab</arm_group_label>
    <description>Patients treated with denosmab</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        tion Osteoporotic patients who admit to our hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe osteoporotic patients

        Exclusion Criteria:

          -  cancer, hypercalcemia, etc (i.e. patients who could not use bisphosphonate, denosmab,
             teriparatide)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Niimi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tomidahama Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui Niimi, MD, PhD</last_name>
    <phone>(81)-59-365-0023</phone>
    <email>furikakefuri@hotmail.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tomidahama Hospital</name>
      <address>
        <city>Yokkaichi</city>
        <state>Mie</state>
        <zip>510-8008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Niimi, MD, PhD</last_name>
      <phone>(81)-59-365-0023</phone>
      <email>furikakefuri@hotmail.co.jp</email>
    </contact>
    <investigator>
      <last_name>Rui Niimi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2014</study_first_submitted>
  <study_first_submitted_qc>June 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tomidahama Hospital</investigator_affiliation>
    <investigator_full_name>Toshihiko Kono</investigator_full_name>
    <investigator_title>Head of Hospital</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>BMD</keyword>
  <keyword>teriparatide</keyword>
  <keyword>bisphosphonate</keyword>
  <keyword>denosmab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

